Showing results (371-380 of 398) with videos related to

Sort By:
Pageof 40
The Oncologist|July 14, 2017
Clinical Application of Targeted Deep Sequencing in Solid-Cancer Patients and Utility for Biomarker-Selected Clinical TrialsSeung Tae Kim, Kyoung-Mee Kim, Nayoung K D Kim, et al.
The New England Journal of Medicine|September 18, 2020
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaThomas Powles, Se Hoon Park, Eric Voog, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinationsLorena Incorvaia, Fernando Sabino Marques Monteiro, Francesco Massari, et al.
The New England Journal of Medicine|June 2, 2021
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial CarcinomaDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
Future Oncology (London, England)|March 15, 2023
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summaryDean F Bajorin, J Alfred Witjes, Jürgen E Gschwend, et al.
The Lancet. Oncology|March 1, 2023
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label studyToni K Choueiri, Masatoshi Eto, Robert Motzer, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2025
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 studyCamillo Porta, Francesco Massari, Tarek Taha, et al.
The Lancet. Oncology|September 24, 2020
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trialThomas Powles, Michiel S van der Heijden, Daniel Castellano, et al.
The New England Journal of Medicine|October 22, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder CancerThomas Powles, Ariel G Kann, Daniel Castellano, et al.
European Urology|February 28, 2024
Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyJonathan E Rosenberg, Ronac Mamtani, Guru P Sonpavde, et al.
Pageof 40